Covered recipient · General Payments record
PARVEZ S MANTRY
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$302,443.12
261 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $208,697.63 | 60 |
| Consulting Fee | $60,822.50 | 13 |
| Travel and Lodging | $17,133.11 | 63 |
| Food and Beverage | $8,234.88 | 122 |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,555.00 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $103,930.15 | 55 |
| Novo Nordisk Inc | $73,810.47 | 29 |
| Amgen Inc. | $39,781.14 | 59 |
| Gilead Sciences, Inc. | $28,319.38 | 41 |
| Intercept Pharmaceuticals, Inc. | $19,653.96 | 20 |
| Ipsen Biopharmaceuticals, Inc | $19,302.08 | 12 |
| Boston Scientific Corporation | $8,891.51 | 7 |
| ABBVIE INC. | $6,222.62 | 18 |
| Eisai Inc. | $2,003.06 | 5 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $206.30 | 4 |
| Mirum Pharmaceuticals, Inc. | $183.77 | 4 |
| Intra-Sana Laboratories | $32.51 | 2 |
| E.R. Squibb & Sons, L.L.C. | $32.44 | 2 |
| Alkermes, Inc. | $30.54 | 1 |
| Mallinckrodt Hospital Products Inc. | $21.61 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.58 | 1 |
Page 4 of 6; records 151–200 of 261 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PARVEZ S MANTRY
NPI 1770528697 · CMS profile ID 80276
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 6; records 151–200 of 261 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1770528697?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PARVEZ S MANTRY, NPI 1770528697, CMS profile ID 80276. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 261 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770528697?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). PARVEZ S MANTRY, NPI 1770528697, CMS profile ID 80276. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 261 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770528697?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- PARVEZ S MANTRY, NPI 1770528697, CMS profile ID 80276, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 261 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1770528697?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
261 matching records · $302,443.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 261.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | $140.03 | 07/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285672 | CMS |
| ABBVIE INC. | $120.00 | 06/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203014015 | CMS |
| ABBVIE INC. | $875.44 | 06/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203014017 | CMS |
| ABBVIE INC. | $190.63 | 06/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203014019 | CMS |
| Amgen Inc. | $1,800.00 | 06/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226914939 | CMS |
| Amgen Inc. | $2,700.00 | 06/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226922775 | CMS |
| ABBVIE INC. | $21.23 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203014013 | CMS |
| Madrigal Pharmaceuticals | $3,878.00 | 06/26/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285668 | CMS |
| Madrigal Pharmaceuticals | $4,935.00 | 06/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285664 | CMS |
| Madrigal Pharmaceuticals | $126.46 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285666 | CMS |
| Amgen Inc. | $238.45 | 06/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226891620 | CMS |
| Amgen Inc. | $6.00 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227208888 | CMS |
| Amgen Inc. | $121.15 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228660344 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.25 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184558106 | CMS |
| Gilead Sciences, Inc. | $20.77 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234520471 | CMS |
| Amgen Inc. | $121.84 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228660340 | CMS |
| Gilead Sciences, Inc. | $340.61 | 06/17/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234367394 | CMS |
| Madrigal Pharmaceuticals | $24.01 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285662 | CMS |
| Amgen Inc. | $110.32 | 06/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228660350 | CMS |
| Boston Scientific Corporation | $48.59 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181400126 | CMS |
| Madrigal Pharmaceuticals | $3,878.00 | 06/12/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285660 | CMS |
| Amgen Inc. | $345.04 | 06/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226877345 | CMS |
| Novo Nordisk Inc | $121.84 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188717890 | CMS |
| Madrigal Pharmaceuticals | $3,878.00 | 06/05/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285658 | CMS |
| Boston Scientific Corporation | $127.05 | 06/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181400124 | CMS |
| Eisai Inc. | $860.00 | 05/30/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244503844 | CMS |
| Madrigal Pharmaceuticals | $3,878.00 | 05/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285656 | CMS |
| Eisai Inc. | $18.47 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244503842 | CMS |
| Eisai Inc. | $1,075.00 | 05/26/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244503848 | CMS |
| Gilead Sciences, Inc. | $22.11 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234504083 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.19 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184558098 | CMS |
| ABBVIE INC. | $69.74 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203014011 | CMS |
| Gilead Sciences, Inc. | $27.94 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234451936 | CMS |
| Amgen Inc. | $2,925.00 | 05/08/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226886253 | CMS |
| Amgen Inc. | $450.00 | 05/08/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226889700 | CMS |
| Gilead Sciences, Inc. | $32.62 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234425698 | CMS |
| Madrigal Pharmaceuticals | $114.00 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285654 | CMS |
| Amgen Inc. | $114.76 | 04/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228660346 | CMS |
| Amgen Inc. | $246.44 | 04/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226922827 | CMS |
| Amgen Inc. | $84.67 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228660360 | CMS |
| Amgen Inc. | $900.00 | 04/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226895115 | CMS |
| Ipsen Biopharmaceuticals, Inc | $4,312.00 | 04/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208830203 | CMS |
| Ipsen Biopharmaceuticals, Inc | $120.61 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208830207 | CMS |
| Madrigal Pharmaceuticals | $3,878.00 | 04/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285650 | CMS |
| Madrigal Pharmaceuticals | $98.81 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285652 | CMS |
| ABBVIE INC. | $21.11 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203014009 | CMS |
| Ipsen Biopharmaceuticals, Inc | $15.87 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208830201 | CMS |
| Gilead Sciences, Inc. | $23.51 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234489336 | CMS |
| Madrigal Pharmaceuticals | $3,878.00 | 04/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248285648 | CMS |
| Novo Nordisk Inc | $261.32 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188218099 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $569,293.58 | 261 |
| PY2024 | Principal investigator | $560,095.99 | 270 |
| PY2023 | Principal investigator | $611,008.07 | 164 |
| PY2022 | Principal investigator | $275,708.61 | 76 |
| PY2021 | Principal investigator | $524,314.75 | 357 |
| PY2020 | Principal investigator | $1,871,030.58 | 259 |
| PY2019 | Principal investigator | $996,131.00 | 217 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
261 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,700.00 | 12/24/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171330 |
| Principal investigator 1 | Genentech, Inc. | $1,100.00 | 12/19/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625086 |
| Principal investigator 1 | Genentech, Inc. | $600.00 | 12/19/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625100 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 12/19/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625114 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 12/19/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546351 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 12/19/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,786.00 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $123.50 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131610 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $123.50 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131616 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $252.20 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131618 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $65.00 | 12/19/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131620 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,924.00 | 12/18/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171310 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,470.00 | 12/11/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171242 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,331.57 | 12/11/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171306 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 12/04/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171308 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,353.00 | 12/04/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131602 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 12/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625090 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 12/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625094 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 12/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625096 |
| Principal investigator 1 | Genentech, Inc. | $2,175.00 | 12/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625105 |
| Principal investigator 1 | Genentech, Inc. | $11,784.00 | 12/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625109 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 12/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625118 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,067.00 | 11/25/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546349 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,660.36 | 11/20/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546347 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,000.00 | 11/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546343 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 11/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 11/14/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131600 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 11/13/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171240 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $453.50 | 11/13/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171300 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $928.50 | 11/13/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171304 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,000.00 | 11/13/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211415311 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 11/07/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171328 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,353.00 | 11/07/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131594 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 11/07/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.50 | 11/07/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131598 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $2,951.00 | 11/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171302 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 11/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625063 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 11/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625067 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 11/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625071 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 11/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625075 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 11/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625079 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 11/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625084 |
| Principal investigator 1 | Sirtex Medical Inc | $1,000.00 | 11/01/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918519 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 10/29/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546339 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 10/29/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546341 |
| Principal investigator 1 | Genentech, Inc. | $33,149.00 | 10/22/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624997 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 10/22/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625007 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 10/22/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625011 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 10/22/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625022 |
| Principal investigator 1 | Genentech, Inc. | $4,675.00 | 10/22/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625045 |
| Principal investigator 1 | Genentech, Inc. | $11,784.00 | 10/22/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625054 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 10/17/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624981 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 10/17/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625003 |
| Principal investigator 1 | Genentech, Inc. | $2,559.00 | 10/17/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625058 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 10/16/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546333 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $98.00 | 10/16/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546335 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 10/16/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,043.00 | 10/16/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131590 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $514.80 | 10/16/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131592 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $453.50 | 10/14/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171298 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,053.50 | 10/09/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171296 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 10/08/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624995 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 10/08/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625029 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 10/08/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625037 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624986 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624991 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625000 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625013 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625018 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625025 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625033 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625041 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 10/01/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211625050 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $414.96 | 09/23/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,830.00 | 09/23/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131584 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $804.30 | 09/23/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131586 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,772.70 | 09/23/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131588 |
| Principal investigator 1 | Genentech, Inc. | $6,660.00 | 09/19/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624944 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,498.50 | 09/18/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171288 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $508.00 | 09/18/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171292 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,331.57 | 09/18/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171294 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $600.00 | 09/18/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546325 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 09/18/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546327 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 09/18/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.50 | 09/18/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131580 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 09/18/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131582 |
| Principal investigator 1 | Bausch Health US, LLC | $1,670.00 | 09/11/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843364 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $10,834.20 | 09/11/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171290 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 09/10/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624927 |
| Principal investigator 1 | Genentech, Inc. | $18,163.00 | 09/10/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624948 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 09/10/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624963 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,920.00 | 09/04/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546323 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $493.70 | 09/04/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416054 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 08/22/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171312 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 08/19/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171238 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,025.05 | 08/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546315 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 08/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546317 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 08/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546319 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 08/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546321 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,000.00 | 08/13/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211419581 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,719.60 | 08/12/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211418847 |
| Principal investigator 1 | Bausch Health US, LLC | $340.00 | 08/08/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843368 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 08/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171286 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $493.70 | 08/06/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416046 |
| Principal investigator 1 | Sirtex Medical Inc | $1,000.00 | 08/01/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.50 | 07/31/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131578 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $170.00 | 07/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211418843 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 07/18/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624937 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $325.85 | 07/18/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416738 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $21,788.91 | 07/18/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211418845 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $22,366.91 | 07/18/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211419579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $123.50 | 07/04/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131572 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 07/04/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131574 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 07/04/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131576 |
| Principal investigator 1 | Genentech, Inc. | $4,335.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624924 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624931 |
| Principal investigator 1 | Genentech, Inc. | $4,341.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624934 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624940 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624950 |
| Principal investigator 1 | Genentech, Inc. | $600.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624954 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624959 |
| Principal investigator 1 | Genentech, Inc. | $11,784.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624967 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624972 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624976 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $414.96 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546275 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,057.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546277 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $98.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546279 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546281 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546283 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546285 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $98.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546287 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546289 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546291 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546293 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $600.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546295 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546297 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546299 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $600.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546301 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $150.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546303 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $193.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546305 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546307 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546309 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546311 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $98.00 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,752.00 | 06/24/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131564 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 06/24/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131566 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 06/24/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131568 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $123.50 | 06/24/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131570 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $378.35 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211418849 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $402.45 | 06/24/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211419585 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $11,857.66 | 06/19/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211415317 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,035.00 | 06/12/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546269 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 06/12/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546271 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 06/12/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,782.00 | 06/12/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131554 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $16,000.00 | 06/12/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131556 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,600.00 | 06/12/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131558 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,184.00 | 06/12/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131560 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,250.00 | 06/12/2025 | Covered Recipient Teaching Hospital METHODIST DALLAS MEDICAL CENTER | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184131562 |
| Principal investigator 1 | Genentech, Inc. | $665.00 | 06/11/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624896 |
| Principal investigator 1 | Genentech, Inc. | $150.00 | 06/11/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624902 |
| Principal investigator 1 | Bausch Health US, LLC | $1,255.41 | 06/05/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843378 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,293.73 | 06/05/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211417423 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 06/04/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624891 |
| Principal investigator 1 | Genentech, Inc. | $11,784.00 | 05/28/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624899 |
| Principal investigator 1 | Genentech, Inc. | $14,730.00 | 05/28/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624912 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $21,788.91 | 05/28/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211419583 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,917.77 | 05/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546259 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,200.00 | 05/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546261 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 05/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546263 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.00 | 05/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546265 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $98.00 | 05/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546267 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $325.85 | 05/22/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416050 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 05/16/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171324 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $175.00 | 05/16/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171326 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 05/15/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171282 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,217.50 | 05/15/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171284 |
| Principal investigator 1 | Bausch Health US, LLC | $1,564.90 | 05/13/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843382 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 05/08/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546253 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 05/08/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546255 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 05/08/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546257 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,000.00 | 05/08/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416052 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,784.00 | 04/28/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546249 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,470.00 | 04/23/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171322 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,231.00 | 04/23/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546251 |
| Principal investigator 1 | Sirtex Medical Inc | $1,500.00 | 04/15/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918515 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $221.00 | 04/10/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171274 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $453.50 | 04/10/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171276 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $928.50 | 04/10/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171278 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,269.50 | 04/10/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171280 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 04/09/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624907 |
| Principal investigator 1 | Genentech, Inc. | $2,833.00 | 04/09/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624917 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 04/09/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624920 |
| Principal investigator 1 | Bausch Health US, LLC | $1,648.40 | 04/07/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843388 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $378.35 | 04/04/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211420311 |
| Principal investigator 1 | Bausch Health US, LLC | $1,500.00 | 04/01/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843391 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,648.00 | 03/21/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171320 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $378.35 | 03/20/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211415315 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $378.35 | 03/20/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416048 |
| Principal investigator 1 | Genentech, Inc. | $11,784.00 | 03/19/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624864 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $414.96 | 03/19/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546247 |
| Principal investigator 1 | Sirtex Medical Inc | $125.00 | 03/17/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918511 |
| Principal investigator 1 | Sirtex Medical Inc | $125.00 | 03/17/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918513 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $225.00 | 03/11/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546243 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 03/11/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546245 |
| Principal investigator 1 | Bausch Health US, LLC | $1,946.23 | 03/05/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843371 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,579.18 | 03/04/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546241 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $928.50 | 02/27/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171256 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $232.50 | 02/27/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171266 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $2,899.00 | 02/27/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171268 |
| Principal investigator 1 | Genentech, Inc. | $600.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624834 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624838 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624850 |
| Principal investigator 1 | Genentech, Inc. | $1,727.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624869 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $125.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171314 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,105.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171316 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 02/26/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM CLINICAL | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171318 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 02/25/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624888 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $170.00 | 02/20/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171232 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,105.00 | 02/20/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171234 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $2,033.20 | 02/20/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171236 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $526.15 | 02/20/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211415313 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,000.00 | 02/20/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211420309 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $15,914.96 | 02/13/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416044 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 02/07/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624854 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 02/07/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624857 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171230 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,600.00 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171258 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $578.50 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171260 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,053.50 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171262 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $928.50 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171264 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $170.00 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171270 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $453.50 | 02/06/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171272 |
| Principal investigator 1 | Genentech, Inc. | $14,365.00 | 02/03/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624841 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $733.35 | 01/30/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211416042 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $14,330.91 | 01/30/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211417421 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $2,033.20 | 01/16/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171226 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $170.00 | 01/16/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171228 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $13,895.50 | 01/16/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171244 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $325.85 | 01/16/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements | No dispute reported | 06/30/2026 | 1211417419 |
| Principal investigator 1 | Genentech, Inc. | $12,462.00 | 01/14/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624861 |
| Principal investigator 1 | Sirtex Medical Inc | $1,500.00 | 01/14/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918509 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 01/09/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624847 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 01/09/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624880 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,008.07 | 01/09/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171246 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $2,243.80 | 01/09/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171248 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,498.50 | 01/09/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171250 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $358.50 | 01/09/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171252 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $453.50 | 01/09/2025 | Non-covered Recipient Entity METHODIST HEALTH SYSTEM | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | No dispute reported | 06/30/2026 | 1248171254 |
| Principal investigator 1 | Bausch Health US, LLC | $6,648.90 | 01/07/2025 | Non-covered Recipient Entity Methodist Health System Clinical Research Institute | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224843374 |
| Principal investigator 1 | Genentech, Inc. | $570.00 | 01/07/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624845 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 01/07/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624874 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $75.00 | 01/07/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546237 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $225.00 | 01/07/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546239 |
| Principal investigator 1 | Sirtex Medical Inc | $3,952.00 | 01/07/2025 | Covered Recipient Teaching Hospital Methodist Dallas Medical Center | DOORwaY Study | No dispute reported | 06/30/2026 | 1248918507 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 01/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624877 |
| Principal investigator 1 | Genentech, Inc. | $600.00 | 01/02/2025 | Non-covered Recipient Entity METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624884 |